|B-Raf/VEGFR-2 Inhibitor RAF265 (Code C61311)|
|Terms & Properties|
Preferred Name: B-Raf/VEGFR-2 Inhibitor RAF265
Definition: An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.
NCI-GLOSS Definition: A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor.
Display Name: B-Raf/VEGFR-2 Inhibitor RAF265
Label: B-Raf/VEGFR-2 Inhibitor RAF265
NCI Metathesaurus Link: C1831810 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|B-Raf/VEGFR-2 Inhibitor RAF265|
External Source Codes:
|PDQ Closed Trial Search ID||484456|
|PDQ Open Trial Search ID||484456 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|